Developer docs
API playgroundTry for free, no card

Search company profiles

Resyca

Full company profile

uuid000kcs1

Namestring
Resyca
Legal namestring
Resyca B.V.
Websiteurl
resyca.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Resyca is a Netherlands-based medical device company founded in 2020 as a joint venture between Medspray and Bespak (formerly part of Recipharm, now standalone and backed by EQT Private Equity). The company develops syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations, using proprietary silicon micro-pore nozzle chip technology manufactured via semiconductor processes. The platform exploits the Rayleigh breakup principle to generate gentle, propellant-free aerosol droplets that preserve the molecular integrity of fragile biologics, mRNA, and other complex formulations, addressing a key limitation of propellant-based metered dose inhalers and dry powder inhalers that are designed for microgram-level potent drugs. Its product portfolio comprises four devices: PFSI (pre-filled syringe inhaler delivering over 60% lung deposition), Pulmospray (single-use disposable nebuliser for clinical settings), Ultra Soft Nasal Pump Spray (multi-dose nasal delivery for nose-to-brain targeting), and Soft Nasal Spray Adaptor (single-use CE-marked nasal device with up to 50% nasal cavity coverage).

Resyca operates exclusively as a B2B company serving pharmaceutical and biotech partners developing novel drug-device combination products. Its revenue model combines upfront and milestone-based licensing fees, ongoing royalties on partner net sales, device supply contracts (clinical and commercial), and end-to-end development services spanning feasibility, formulation optimization, device selection, regulatory submissions, and fill-finish. Named customers include Cyrano Therapeutics (exclusive license for smell loss treatment), Silo Pharma (intranasal PTSD drug), Thaerapy BV (pulmonary arterial hypertension), and strategic collaborators Stevanato Group and Aero Pump. Manufacturing is handled through parent Bespak (King's Lynn, UK) and Medspray (Enschede, Netherlands), with commercial operations anchored in Munich, Germany.

The company holds ISO 13485 certification (since 2022), EU MDR certification (since January 2025), and FDA QSR compliance, enabling support for combination product submissions in both EU and US markets. Resyca's strategic positioning targets high-growth therapeutic areas where existing inhaler technologies are inadequate, including biologics, mRNA therapeutics, nasal vaccines, and nose-to-brain CNS delivery, positioning the company as a platform enabling partner pipelines rather than a drug developer itself.

Short descriptiontext

Resyca is a Netherlands-based medical device company developing syringe-based soft mist inhalers and nasal sprays for liquid pharmaceutical formulations. It serves pharmaceutical and biotech partners through licensing, device supply, and development services, using proprietary silicon micro-pore nozzle technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEnschede, Netherlands
HQ citystring
Enschede
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
soft mist inhalers, nasal drug delivery, drug-device combination products, pre-filled syringe inhalers, inhalation drug delivery
Industry3 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Inhalation Drug Delivery Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Device Licensing and Royalties
TypeLicensing Royalties
Description

Licensing of proprietary soft mist technology to pharmaceutical partners. Partners receive exclusive or non-exclusive rights to use Resyca's technology for specific drug products. Revenue includes upfront milestones and ongoing royalties based on net sales of marketed products.

resyca.com
2Device Supply and Manufacturing
TypeHardware Sales
Description

Supply of soft mist inhaler devices and components to pharmaceutical partners. Includes both clinical trial supply and commercial-scale supply. Manufacturing supported by Bespak and Medspray.

resyca.com
3Development Services
TypeProfessional Services
Description

Comprehensive services spanning early-stage feasibility, formulation optimisation, device selection, regulatory submissions, clinical trial supply, and fill-finish services. Full end-to-end partnership from concept to market.

resyca.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1PFSI
Description

Pre-Filled Syringe Soft Mist Inhaler - A ready-to-use, patient-friendly platform combining high-performance drug delivery with everyday convenience.

resyca.com
+3 more records
Core offering1 text field

Resyca develops and manufactures syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations. The company's four product platforms — PFSI, Pulmospray, Ultra Soft Nasal Pump Spray, and Soft Nasal Spray Adaptor — leverage proprietary Rayleigh spray nozzle technology built on silicon micro-pore chips. Resyca sells these drug-device combination platforms to pharmaceutical and biotech partners through licensing, device supply contracts, and end-to-end development services from feasibility through commercial launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Over 60% lung deposition achieved with PFSI device
+6 more records
Product overview1 text field

Resyca offers a portfolio of four distinct soft mist drug delivery platforms: PFSI (Pre-Filled Syringe Inhaler) and Pulmospray for pulmonary inhalation delivery, and Ultra Soft Nasal Pump Spray and Soft Nasal Spray Adaptor for nasal delivery applications. All platforms utilise proprietary Medspray micro-nozzle technology based on silicon micro-pore chips that generate gentle, propellant-free soft mist aerosols via Rayleigh breakup theory. The PFSI and Soft Nasal Spray Adaptor support pre-filled syringe formats for clinical and commercial use, while Pulmospray offers on-site fillable single-use delivery. The Ultra Soft Nasal Pump Spray provides multidose nasal delivery with precise olfactory targeting for nose-to-brain therapies. These platforms are designed for liquid formulations of both biologics and small molecules, offering end-to-end services from early-stage development through commercial launch.

Product and service4 records
1PFSI (Pre-Filled Syringe Inhaler)
CategorySoft Mist Inhaler Device
Description

A ready-to-use, patient-friendly soft mist inhaler that combines high-performance drug delivery with everyday convenience. Built on a 1mL pre-filled glass syringe (Stevanato Alba), it delivers over 60% of the dose deep into the lungs using proprietary Rayleigh spray nozzle technology. Compact, pocket-sized, available in reusable and disposable configurations, designed for pharmaceutical partners developing pulmonary drug-device combination products.

2Pulmospray
CategorySoft Mist Nebuliser Device
Description

A single-use, disposable soft mist nebuliser with a 1mL plastic syringe fillable on-site with desired medication. CE-marked, propellant-free device using proprietary Rayleigh spray nozzle technology for gentle, efficient aerosolisation. Designed for hospitals, clinical studies, and acute treatments where 53–61% lung dose and single-use sterile systems are required.

3Ultra Soft Nasal Pump Spray
CategoryNasal Drug Delivery Device
Description

A multi-dose precision nasal drug delivery device co-developed with Aero Pump, delivering a fine, low-velocity mist with 18× slower spray velocity using proprietary Rayleigh spray nozzle technology. Available in 45µL and 70µL pump volumes with 5–30mL fill capacities, designed for accurate deposition in posterior and olfactory regions for CNS therapies, nasal vaccines, and sensitive biologics.

4Soft Nasal Spray Adaptor
CategoryNasal Drug Delivery Device
Description

A CE-marked single-use nasal administration device designed for liquids, used with a Luer-Lock syringe. Generates a tuneable soft mist with gentle low-shear spray principle for safe delivery of sensitive drugs, providing up to 50% coverage of the nasal cavity and optimal coverage of the olfactory region for nose-to-brain targeting.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialist inhalation drug delivery company (now part of Philip Morris) developing dry powder and soft mist inhaler platforms for pharma partners. Direct comparable because Resyca's CTO and COO both held senior roles at Vectura, and Vectura targets the same pharma combination product licensing model across respiratory indications.

2Boehringer Ingelheim (Respimat)
TypeBroad incumbent
Description

Owner of the Respimat soft mist inhaler, the established market-leading propellant-free inhaler used in marketed products such as Spiriva Respimat and Combivent Respimat. Direct comparable in soft mist inhalation technology and pharma combination products, but as a large incumbent pharmaceutical manufacturer rather than a specialist device licensor.

TypeDirect peer
Description

Major drug delivery device manufacturer offering nasal spray pumps, inhalation devices, and injectable systems to pharma partners. Comparable because Aptar competes for the same pharma combination product RFPs that Resyca targets, with overlapping nasal pump spray capabilities.

TypeDirect peer
Description

Drug delivery device company with a portfolio spanning nasal, ophthalmic, inhalation, and injectable delivery systems. Comparable because Nemera offers competing nasal spray and inhalation platforms to the same pharma customer base, with similar licensing-plus-supply commercial models.

TypeDirect peer
Description

Pharmaceutical glass primary packaging and drug delivery systems manufacturer, including the Alba EZ-fill pre-filled syringe platform that Resyca integrates into PFSI. Comparable as both a strategic partner and a competing supplier of pre-fillable drug-device combination solutions for injectable and inhaled biologics.

TypeBroad incumbent
Description

Global leader in injectable drug delivery and containment including pre-filled syringe components, inhalation devices, and elastomeric seals. Comparable because West competes for pharma combination product device supply and is a natural strategic acquirer of specialised platforms like Resyca.

TypeBroad incumbent
Description

Large diversified medical device and drug delivery company with significant presence in pre-filled syringes, injection systems, and respiratory drug delivery. Comparable as a broad incumbent competing for pharma device partnerships across nasal, pulmonary, and injectable delivery formats.

TypeDirect peer
Description

Pharmaceutical and biotech packaging specialist including glass syringes, pre-fillable systems, and inhalation device components. Comparable because Gerresheimer supplies primary packaging and drug-device combination components to the same pharma customer base that Resyca serves.

TypeBroad incumbent
Description

Major CDMO with drug delivery capabilities spanning inhalation, nasal, and injectable formats. Comparable as a partner-and-competitor for pharma combination product development services, particularly for soft mist and nasal biologic delivery programs.

TypeEmerging player
Description

CDMO with growing inhalation and nasal drug delivery capabilities including particle engineering and device formulation services. Comparable as a newer entrant in soft mist and nasal spray combination product development targeting similar pharma and biotech customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resyca

Inhalation Drug Delivery Devicesresyca.com

Resyca is a Netherlands-based medical device company developing syringe-based soft mist inhalers and nasal sprays for liquid pharmaceutical formulations. It serves pharmaceutical and biotech partners through licensing, device supply, and development services, using proprietary silicon micro-pore nozzle technology.

What Resyca does

Resyca is a Netherlands-based medical device company founded in 2020 as a joint venture between Medspray and Bespak (formerly part of Recipharm, now standalone and backed by EQT Private Equity). The company develops syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations, using proprietary silicon micro-pore nozzle chip technology manufactured via semiconductor processes. The platform exploits the Rayleigh breakup principle to generate gentle, propellant-free aerosol droplets that preserve the molecular integrity of fragile biologics, mRNA, and other complex formulations, addressing a key limitation of propellant-based metered dose inhalers and dry powder inhalers that are designed for microgram-level potent drugs. Its product portfolio comprises four devices: PFSI (pre-filled syringe inhaler delivering over 60% lung deposition), Pulmospray (single-use disposable nebuliser for clinical settings), Ultra Soft Nasal Pump Spray (multi-dose nasal delivery for nose-to-brain targeting), and Soft Nasal Spray Adaptor (single-use CE-marked nasal device with up to 50% nasal cavity coverage).

Resyca operates exclusively as a B2B company serving pharmaceutical and biotech partners developing novel drug-device combination products. Its revenue model combines upfront and milestone-based licensing fees, ongoing royalties on partner net sales, device supply contracts (clinical and commercial), and end-to-end development services spanning feasibility, formulation optimization, device selection, regulatory submissions, and fill-finish. Named customers include Cyrano Therapeutics (exclusive license for smell loss treatment), Silo Pharma (intranasal PTSD drug), Thaerapy BV (pulmonary arterial hypertension), and strategic collaborators Stevanato Group and Aero Pump. Manufacturing is handled through parent Bespak (King's Lynn, UK) and Medspray (Enschede, Netherlands), with commercial operations anchored in Munich, Germany.

The company holds ISO 13485 certification (since 2022), EU MDR certification (since January 2025), and FDA QSR compliance, enabling support for combination product submissions in both EU and US markets. Resyca's strategic positioning targets high-growth therapeutic areas where existing inhaler technologies are inadequate, including biologics, mRNA therapeutics, nasal vaccines, and nose-to-brain CNS delivery, positioning the company as a platform enabling partner pipelines rather than a drug developer itself.

Resyca firmographics

Firmographics
Name
Resyca
Legal name
Resyca B.V.
Website
https://resyca.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Resyca is a Netherlands-based medical device company developing syringe-based soft mist inhalers and nasal sprays for liquid pharmaceutical formulations. It serves pharmaceutical and biotech partners through licensing, device supply, and development services, using proprietary silicon micro-pore nozzle technology.
Ownership category
akta.pro rank

Resyca industry classification

Industry
Product category
Inhalation Drug Delivery Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

Keywords

  • Soft mist inhalers
  • Nasal drug delivery
  • Drug-device combination products
  • Pre-filled syringe inhalers
  • Inhalation drug delivery

Where Resyca is headquartered

Location

Headquarters

HQ city
Enschede
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Resyca business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Device Licensing and Royalties: Licensing of proprietary soft mist technology to pharmaceutical partners. Partners receive exclusive or non-exclusive rights to use Resyca's technology for specific drug products. Revenue includes upfront milestones and ongoing royalties based on net sales of marketed products.
  2. Device Supply and Manufacturing: Supply of soft mist inhaler devices and components to pharmaceutical partners. Includes both clinical trial supply and commercial-scale supply. Manufacturing supported by Bespak and Medspray.
  3. Development Services: Comprehensive services spanning early-stage feasibility, formulation optimisation, device selection, regulatory submissions, clinical trial supply, and fill-finish services. Full end-to-end partnership from concept to market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Resyca product offering

Product offering

Core offering

Resyca develops and manufactures syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations. The company's four product platforms — PFSI, Pulmospray, Ultra Soft Nasal Pump Spray, and Soft Nasal Spray Adaptor — leverage proprietary Rayleigh spray nozzle technology built on silicon micro-pore chips. Resyca sells these drug-device combination platforms to pharmaceutical and biotech partners through licensing, device supply contracts, and end-to-end development services from feasibility through commercial launch.

Product overview

Resyca offers a portfolio of four distinct soft mist drug delivery platforms: PFSI (Pre-Filled Syringe Inhaler) and Pulmospray for pulmonary inhalation delivery, and Ultra Soft Nasal Pump Spray and Soft Nasal Spray Adaptor for nasal delivery applications. All platforms utilise proprietary Medspray micro-nozzle technology based on silicon micro-pore chips that generate gentle, propellant-free soft mist aerosols via Rayleigh breakup theory. The PFSI and Soft Nasal Spray Adaptor support pre-filled syringe formats for clinical and commercial use, while Pulmospray offers on-site fillable single-use delivery. The Ultra Soft Nasal Pump Spray provides multidose nasal delivery with precise olfactory targeting for nose-to-brain therapies. These platforms are designed for liquid formulations of both biologics and small molecules, offering end-to-end services from early-stage development through commercial launch.

Differentiator

Problem solved

Functional benefit

Brands

  • PFSI: Pre-Filled Syringe Soft Mist Inhaler - A ready-to-use, patient-friendly platform combining high-performance drug delivery with everyday convenience.
  • Pulmospray
  • Ultra Soft Nasal Pump Spray
  • Soft Nasal Spray Adaptor

Products and services

  • PFSI (Pre-Filled Syringe Inhaler) A ready-to-use, patient-friendly soft mist inhaler that combines high-performance drug delivery with everyday convenience. Built on a 1mL pre-filled glass syringe (Stevanato Alba), it delivers over 60% of the dose deep into the lungs using proprietary Rayleigh spray nozzle technology. Compact, pocket-sized, available in reusable and disposable configurations, designed for pharmaceutical partners developing pulmonary drug-device combination products.
  • Pulmospray A single-use, disposable soft mist nebuliser with a 1mL plastic syringe fillable on-site with desired medication. CE-marked, propellant-free device using proprietary Rayleigh spray nozzle technology for gentle, efficient aerosolisation. Designed for hospitals, clinical studies, and acute treatments where 53–61% lung dose and single-use sterile systems are required.
  • Ultra Soft Nasal Pump Spray A multi-dose precision nasal drug delivery device co-developed with Aero Pump, delivering a fine, low-velocity mist with 18× slower spray velocity using proprietary Rayleigh spray nozzle technology. Available in 45µL and 70µL pump volumes with 5–30mL fill capacities, designed for accurate deposition in posterior and olfactory regions for CNS therapies, nasal vaccines, and sensitive biologics.
  • Soft Nasal Spray Adaptor A CE-marked single-use nasal administration device designed for liquids, used with a Luer-Lock syringe. Generates a tuneable soft mist with gentle low-shear spray principle for safe delivery of sensitive drugs, providing up to 50% coverage of the nasal cavity and optimal coverage of the olfactory region for nose-to-brain targeting.

Quantifiable outcome

  • Over 60% lung deposition achieved with PFSI device
  • +6 more outcomes

Companies that use Resyca

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Resyca technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Resyca partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Resyca competitors and assessment

Company assessment

Direct peers

  • Vectura: Specialist inhalation drug delivery company (now part of Philip Morris) developing dry powder and soft mist inhaler platforms for pharma partners. Direct comparable because Resyca's CTO and COO both held senior roles at Vectura, and Vectura targets the same pharma combination product licensing model across respiratory indications.
  • Aptar Pharma: Major drug delivery device manufacturer offering nasal spray pumps, inhalation devices, and injectable systems to pharma partners. Comparable because Aptar competes for the same pharma combination product RFPs that Resyca targets, with overlapping nasal pump spray capabilities.
  • Nemera: Drug delivery device company with a portfolio spanning nasal, ophthalmic, inhalation, and injectable delivery systems. Comparable because Nemera offers competing nasal spray and inhalation platforms to the same pharma customer base, with similar licensing-plus-supply commercial models.
  • Stevanato Group: Pharmaceutical glass primary packaging and drug delivery systems manufacturer, including the Alba EZ-fill pre-filled syringe platform that Resyca integrates into PFSI. Comparable as both a strategic partner and a competing supplier of pre-fillable drug-device combination solutions for injectable and inhaled biologics.
  • Gerresheimer: Pharmaceutical and biotech packaging specialist including glass syringes, pre-fillable systems, and inhalation device components. Comparable because Gerresheimer supplies primary packaging and drug-device combination components to the same pharma customer base that Resyca serves.

Broad incumbents

  • Boehringer Ingelheim (Respimat): Owner of the Respimat soft mist inhaler, the established market-leading propellant-free inhaler used in marketed products such as Spiriva Respimat and Combivent Respimat. Direct comparable in soft mist inhalation technology and pharma combination products, but as a large incumbent pharmaceutical manufacturer rather than a specialist device licensor.
  • West Pharmaceutical Services: Global leader in injectable drug delivery and containment including pre-filled syringe components, inhalation devices, and elastomeric seals. Comparable because West competes for pharma combination product device supply and is a natural strategic acquirer of specialised platforms like Resyca.
  • Becton Dickinson (BD): Large diversified medical device and drug delivery company with significant presence in pre-filled syringes, injection systems, and respiratory drug delivery. Comparable as a broad incumbent competing for pharma device partnerships across nasal, pulmonary, and injectable delivery formats.
  • Catalent: Major CDMO with drug delivery capabilities spanning inhalation, nasal, and injectable formats. Comparable as a partner-and-competitor for pharma combination product development services, particularly for soft mist and nasal biologic delivery programs.

Emerging players

  • Hovione: CDMO with growing inhalation and nasal drug delivery capabilities including particle engineering and device formulation services. Comparable as a newer entrant in soft mist and nasal spray combination product development targeting similar pharma and biotech customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Resyca social profiles

Digital presence

Resyca compliance and trust

Trust signal

Compliance3 records

Resyca financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resyca leadership team

Management profile

Number of profiles

Profiles3 records

Resyca funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resyca M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resyca

What does Resyca do?

Resyca develops and manufactures syringe- and cartridge-based soft mist inhaler devices and nasal sprays for liquid pharmaceutical formulations. The company's four product platforms — PFSI, Pulmospray, Ultra Soft Nasal Pump Spray, and Soft Nasal Spray Adaptor — leverage proprietary Rayleigh spray nozzle technology built on silicon micro-pore chips. Resyca sells these drug-device combination platforms to pharmaceutical and biotech partners through licensing, device supply contracts, and end-to-end development services from feasibility through commercial launch.

Is Resyca a public or private company?

Resyca is a private company. It is classified as corporate owned and is currently operating.

When was Resyca founded?

Resyca was founded in 2020. It employs 11 to 50 people.

Where is Resyca based?

Resyca is headquartered in Enschede, Netherlands, in the Europe region.

How does Resyca make money?

Three revenue lines are on record. Device Licensing and Royalties are the primary driver. The others are device Supply and Manufacturing and development Services.

Who are Resyca's main competitors?

Direct peers on record are Vectura, Aptar Pharma, Nemera, Stevanato Group and Gerresheimer. Broad incumbents are Boehringer Ingelheim (Respimat), West Pharmaceutical Services, Becton Dickinson (BD) and Catalent. Hovione is listed as an emerging player.

Does Resyca have an API?

No public API is recorded for Resyca.

What industry is Resyca in?

Resyca's product category is Inhalation Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of IMALAIAE, Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Insider Trading & Hedge Fund Data5 Best Psychedelic Stocks to Buy According to Analysts - Insider MonkeyInsider Monkey published an article ranking the 5 best psychedelic stocks to buy according to analysts, with Silo Pharma, Inc. (NASDAQ:SILO) listed as the fifth pick with a 76.68% price target upside. Silo Pharma reported that its wholly owned subsidiary QwikAgents joined the NVIDIA Developer Program to access AI software ecosystem and development tools for its autonomous AI agent platform, while separately partnering with Resyca to evaluate microchip-based nasal spray technology for its SPC-15 PTSD treatment candidate.BioSpaceSilo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting RequestSilo Pharma engaged Resyca to conduct a robustness study of its SPC-15 nasal spray system for PTSD, evaluating device performance and formulation stability over 30 days. The data are expected to support a planned FDA Type C meeting request for IND strategy and Phase 1 trial design.European BiotechnologyNext stage of growth with a new CEODeborah Jones has been appointed CEO of Enschede-based Resyca BV, which develops soft-mist inhalation technology. She will lead the company's growth, expand partnerships with pharmaceutical and biotech firms, and develop platforms for inhalers and nasal sprays. Jones brings over 20 years of leadership experience, including a role at Proveris Scientific.GlobeNewswireSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15Silo Pharma entered a service agreement with Resyca BV for a drug-device study of its SPC-15 intranasal PTSD treatment. The study aims to provide final device data for the IND, which Silo plans to submit to the FDA this year. The company is also conducting additional SPC-15 studies.Stock TitanPTSD Drug Innovation: Silo Pharma Advances Novel Intranasal Delivery SystemSilo Pharma entered a service agreement with Resyca BV for a drug-device study of its intranasal PTSD drug SPC-15. The study aims to provide final device data for a planned FDA IND submission this year. The company is also conducting additional SPC-15 studies.YahooResyca Receives Medical Device Regulation Certificate From TÜV SÜDResyca BV received MDR certification from TÜV SÜD, confirming its inhalation device design, development, and manufacturing comply with EU standards. The certification streamlines EU submissions for drug-device combination products, helping pharmaceutical partners accelerate market access.Business InsiderResyca Receives Medical Device Regulation Certificate From TÜV SÜDResyca BV received MDR certification from TÜV SÜD, confirming its inhalation device processes meet EU standards. The certification streamlines EU submissions for drug-device combinations and accelerates market access for pharmaceutical partners. Resyca, founded in 2020, is a joint venture between Bespak and Medspray.PharmiWeb.comAero Pump and Resyca Partner to Launch Ultra Soft Nasal Pump Spray, Targeting Precise Nasal Drug Delivery ApplicationsAero Pump and Resyca launched the Ultra Soft Nasal Pump Spray, available for licensing, using Medspray's spray nozzle chip technology for precise nasal drug delivery. The system targets nose-to-brain therapies and nasal vaccination, with services for device customization and regulatory support. The partners plan to expand applications and explore future innovations.PharmiWeb.comAero Pump and Resyca Partner to Launch Ultra Soft Nasal Pump Spray, Targeting Precise Nasal Drug Delivery ApplicationsAero Pump and Resyca launched the Ultra Soft Nasal Pump Spray, available for licensing, using Medspray's spray nozzle chip technology for precise nasal drug delivery. The system targets nose-to-brain therapies and nasal vaccination, with aseptic filling capabilities. The partners plan to expand applications and explore future innovations.YahooAero Pump and Resyca Partner to Launch Ultra Soft Nasal Pump Spray, Targeting Precise Nasal Drug Delivery ApplicationsAero Pump and Resyca launched the Ultra Soft Nasal Pump Spray, available for licensing, combining Resyca's soft mist nozzle technology with Aero Pump's spray systems. The device targets nose-to-brain therapies and nasal vaccination, offering improved coverage and patient comfort. The partners plan to expand applications and continue innovations in nasal drug delivery.